Regulation of Cytokines/Chemokines Release and Anti-Tumor Effect of Expanded Natural Killer (NK) Cells By a Novel Fusion of N-820 (2B8T2M), an IL-15 Superagonist with 4 Single-Chain Anti-CD20 Antibody Domains, Against Rituximab Resistant Burkitt Lymphoma (BL)

Authors

Yaya Chu, New York Medical CollegeFollow
Nang Kham Su, New York Medical College
Emily K. Jeng
Sarah AlterFollow
Peter R. Rhode
John H. LeeFollow
Gaurav Nayyar, New York Medical College
Matthew Barth
Dean A. LeeFollow
Hing C. Wong
Mitchell S. Cairo, New York Medical CollegeFollow

Document Type

Abstract

Publication Date

11-2018

Journal Title

Blood

Department

Pediatrics

Second Department

Health Behavior and Community Health

Recommended Citation

Chu, Y., Su, N., Jeng, E. K., Alter, S., Rhode, P. R., Lee, J. H., Nayyar, G., Barth, M., Lee, D. A., Wong, H. C., & Cairo, M. (2018). Regulation of Cytokines/Chemokines Release and Anti-Tumor Effect of Expanded Natural Killer (NK) Cells By a Novel Fusion of N-820 (2B8T2M), an IL-15 Superagonist with 4 Single-Chain Anti-CD20 Antibody Domains, Against Rituximab Resistant Burkitt Lymphoma (BL). Blood, 132 (Suppl. 1), 3697. Retrieved from https://touroscholar.touro.edu/nymc_fac_abstracts/226